Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the Week 24 visit and the 6-Week Follow-up visit of Corcept Study C-1073-400 (NCT00569582).~* In the opinion of the Investigator, are expected to maintain clinical benefit from mifepristone.~* Women of childbearing potential have a negative serum pregnancy test at Entry.~* Women of childbearing potential must be willing to use non-hormonal, medically acceptable methods of contraception during the study.~* Are able to provide written informed consent~* Are able to return to the investigative site to complete the study evaluations outlined in the protocol.~* Will not use systemic estrogens during the study.~Exclusion Criteria:~* Have an acute or unstable medical problem, which could be aggravated by mifepristone treatment.~* Are taking medications within 14 days of the Entry visit that a) have a large first pass metabolism that is largely mediated by CYP3A4 and which have a narrow therapeutic margin; and/or b) are strong CYP3A4 inhibitors.~* Female patients of reproductive potential, who are pregnant or who are unable or unwilling to use medically acceptable, non-hormonal methods of contraception during the study.~* Have received investigational treatment (drug, biological agent or device) other than CORLUX (mifepristone) within 30 days of Entry~* Have a history of an allergic reaction or intolerance to CORLUX (mifepristone)~* Have uncorrected hypokalemia (potassium level of \<3.5 mEq/L) at Entry. Spironolactone or eplerenone is allowed to control hypokalemia.~* Postmenopausal women with a history of endometrial hyperplasia with atypia or pathological features consistent with endometrial carcinoma.~* Thickened endometrium on the Entry Visit transvaginal ultrasound that has not resolved after induction of menstrual bleeding with progesterone.~* Uncontrolled, clinically significant hypothyroidism or hyperthyroidism.~* Any woman with an intact uterus who has a hemorrhagic disorder or is being treated with an anticoagulant (e.g. warfarin, heparin).~* Have renal failure as defined by a serum creatinine of ≥2.2 mg/dL.~* Elevated total bilirubin \>1.5 ULN, elevated ALT or AST ≥3X the upper limit of normal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: EXPERIMENTAL): Mifepristone 300mg to 1200mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).